Home/Filings/4/0001104659-25-008770
4//SEC Filing

Roberts M Scot 4

Accession 0001104659-25-008770

CIK 0001326190other

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 8:43 PM ET

Size

22.1 KB

Accession

0001104659-25-008770

Insider Transaction Report

Form 4
Period: 2025-01-30
Roberts M Scot
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock, par value $0.0001

    2025-02-01+6,16669,562 total
  • Tax Payment

    Common Stock, par value $0.0001

    2025-02-02$6.64/sh2,316$15,37873,220 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-01+6,1660 total
    Common Stock, par value $0.0001 (6,166 underlying)
  • Exercise/Conversion

    Common Stock, par value $0.0001

    2025-01-30+9,27562,921 total
  • Award

    Common Stock, par value $0.0001

    2025-01-31$5.18/sh+3,184$16,49363,396 total
  • Exercise/Conversion

    Common Stock, par value $0.0001

    2025-02-02+7,77575,536 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-01-30+9,27518,550 total
    Common Stock, par value $0.0001 (9,275 underlying)
  • Tax Payment

    Common Stock, par value $0.0001

    2025-02-01$6.64/sh1,801$11,95967,761 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-02+7,7757,775 total
    Common Stock, par value $0.0001 (7,775 underlying)
  • Tax Payment

    Common Stock, par value $0.0001

    2025-01-30$7.00/sh2,709$18,96360,212 total
Footnotes (7)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
  • [F2]Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
  • [F3]These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2024 through January 31, 2025.
  • [F4]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2024.
  • [F5]The RSUs vest in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date
  • [F6]The RSUs vest in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
  • [F7]The RSUs vest in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date

Issuer

Altimmune, Inc.

CIK 0001326190

Entity typeother

Related Parties

1
  • filerCIK 0001705905

Filing Metadata

Form type
4
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 8:43 PM ET
Size
22.1 KB